Original Article
Preclinical Safety Evaluation of Human Mesenchymal Stem Cell Transplantation in Cerebrum of Nonhuman Primates
International Journal of Toxicology 2014, Vol. 33(5) 403-411 ª The Author(s) 2014 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/1091581814545244 ijt.sagepub.com
Ming Feng1, Yan Li2,3, Qin Han4, Xinjie Bao1, Ming Yang1, Hua Zhu2, Qin Li2, Junji Wei1, Wenbin Ma1, Hong Gao2, Yihua An5, Robert Chunhua Zhao4, Chuan Qin2, and Renzhi Wang1
Abstract The efficacy of stem cell transplantation for promoting recovery of patients with neurological diseases, such as stroke, has been reported in several studies. However, the safety of the intracerebral transplantation of human mesenchymal stem cells (hMSCs) remains unclear. The aim of the study was to evaluate the safety of hMSCs transplanted in cerebrum of Macaca fascicularis and to provide evidence for clinical application. A total of 24 M fascicularis were assigned to 3 groups randomly: low dose (3.0 105 cells/kg), high dose (2.5 106 cells/kg), and the control (normal saline [NS]). Human mesenchymal stem cells or NS were injected into each monkey for 2 times, with an interval of 3 weeks. The injection point was located outside of the right putamen, according to a stereotactic map and preoperative magnetic resonance imaging of the monkeys. Animal health, behavior, biophysical and biochemical parameters, and brain neurological function were routinely monitored over a 6-month period posttransplantation, and the histopathologic examinations were also performed. The results showed that local pathologic damage including local tissue necrosis and inflammation was induced after the injection. The damage of low-dose and high-dose groups was greater than that of the control group, yet over time, the damage could be repaired gradually. No major hMSCs-associated changes were induced from other indicators, and the transplantation of hMSCs in monkeys did not affect total immunoglobulin (Ig) M, total IgG, CD3, CD4, or CD8 values. We therefore conclude that transplantation of hMSCs to the cerebrum represents a safe alternative for clinical application of neurological disorders. Keywords mesenchymal stem cell, cell transplantation, safety, cerebrum, Macaca fascicularis
Introduction Cerebrovascular disease (CVD) is a common and lifethreatening disease that poses a significant public health challenge. He et al1 reported in 2005 that CVD ranked the third among 5 leading causes of death in men and ranked the second in women. A multicenter research in China indicated that CVD was the most prevalent cause of deaths, accounting for 40% of total deaths. However, there remain a limited number of effective therapies for CVD, and patients still had continued deterioration of neurological function following treatment.2-6 Consequently, it is important to develop novel therapies that can limit the extent of neurological damage and improve functional recovery. Human mesenchymal stem cells (hMSCs), usually obtained from bone marrow, can differentiate into a variety of cell types and can facilitate damage repair and structural and functional repair of aged organ. Related studies have shown that hMSCsbased therapies promote recovery of motor function in stroke mice model7 and improved neurologic function following
induced stroke.8 These findings have been confirmed and extended by many other animal studies.9-13 Stem cell treatment has also shown benefits in our prior studies using experimental intracerebral hemorrhage models in rodents and primates.11-13 These properties, together with the fact that MSCs can be
1
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China 2 Institute of Laboratory Animal Sciences, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 3 National Institute for Nutrition and Food Safety, Chinese Center for Disease Control and Prevention, Beijing, China 4 Institute of Basic Medical Sciences, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 5 Beijing Institute of Neurological Surgery, Beijing, China Corresponding Author: Renzhi Wang, Department of Neurosurgery of Peking Union Medical College Hospital, 100730, Beijing, People’s Republic of China. Email: [email protected]
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
404
International Journal of Toxicology 33(5)
readily obtained, rapidly expanded in vitro, and has fewer ethical disputes, make them a promising therapeutic candidates to CVD. However, the safety of intracerebral hMSCs transplantation is still unclear; thus, it is urgent to explore this approach in a clinically relevant model.14 The goal of this study was to evaluate the long-term toxicity associated with repeated intracerebral hMSCs transplantation in nonhuman primates (Macaca fascicularis).
Materials and Methods Animals and Housing A total of 24 M fascicularis (12 male and 12 female; aged 3 to 6 years; weight 4.1 + 0.5 kg) were received from the Experimental Animal Center of the Chinese Academy of Military Medical Sciences. All monkeys were kept single in stainless steel cage at 18 C to 28 C and a relative humidity of 40% to 70%. The primate facility is licensed and accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, and all procedures were approved by the Institutional Animal Care and Use Committee of the Chinese Academy of Medical Sciences (MC-07-6004). Animal experiments and housing procedures were carried out in accordance with the laboratory animal administration rules of the Ministry of Science and Technology of the People’s Republic of China.
weight: low dose (3.0 105 cells/kg), high dose (2.5 106 cells/kg), and the control (phosphate-buffered saline), and the dose is 2.1 and 17.5 times to intended clinical dose (1 107 cells/person, the body weight of one person is assumed to be 70 kg), respectively.
Dosing The animals were fasted overnight prior to surgery. Ketamine (15 mg/kg) and sodium pentobarbital (30 mg/kg) were administered intramuscularly (IM) for the duration of the procedure. Then, the monkeys were placed in a stereotactic frame (Stoelting Co, Illinois) and set the origin coordinates according to a stereotactic map and preoperative magnetic resonance imaging (MRI) scans. The coordinates were recorded and the coordinate origin was set. Generally, the coordinates were AP 16 mm, D 16 mm, and L 14 mm, whereby AP represents the anterior and posterior directions, D represents the depth, and L represents the lateral coordinates. The injection point was located outside of the right putamen, according to a stereotactic map and preoperative MRI of the monkeys. The cells were delivered through 2 injection channels located 1.5 mm apart, and each channel contained 3 injection points spaced 1 mm apart. A total volume of 250 mL was administered at a rate of 40 to 50 mL/min. After a 3-week interval, animals were administered a second round of injections using the same procedure. Penicillin (400 000 units per day, IM) was administered for 3 days after surgery.
Preparation of the HMSCs Bone marrow was collected from healthy adult human volunteers. All participants signed a declaration of informed consent before surgery. The hMSCs were isolated and cultured using a technique that has been detailed in a previous report.15 Briefly, mononuclear cells were isolated from marrow aspirates with Ficoll-Paque density gradient centrifugation. Cells were counted and cultured in Dulbecco Modified Eagle Medium: Nutrient Mixture F-12 (Gibco Co, Los Angeles) with 2% fetal bovine serum (Hyclone Co, Utah), 2 mmol/L L-glutamine (Hyclone), 1 insulin transferrin selenium (Gibco), 109 mol/L dexamethasone (Sigma-Aldrich, St. Louis), 104 mol/L ascorbic acid 2-phosphate (Sigma-Aldrich), 10 ng/mL epidermal growth factor, 100 U/mL penicillin, and 1000 U/mL streptomycin (Gibco) at 3 105 cells/cm2 in a humidified incubator at 37 C with an atmosphere of 5% CO2. The hMSCs adhered to the walls and grew, and nonadherent cells were removed after 24 to 48 hours. When reached 80% to 90% confluence, the cells were digested with 0.125% trypsin and replated at a 1:2 dilution under the same culture conditions, then were collected and prepared for transplantation.
General Observations and Examinations Animals were observed daily following surgery. Skin and fur appearance, vital signs, secretions, upper and lower limb movements, consciousness, and injection region reactions were assessed at 1, 2, and 3 days after cell administration.
Neurological Function Evaluation Each monkey was subjected to neurological function tests at regular time intervals (see Table 1). Scores for neurological function were refined and modified from the Kito score scale and also referenced the ‘‘Neurological Scale for Middle Cerebral Artery Infarction’’ (Table 2). The scale includes a total of 100 scores, including 28 scores for awareness, 22 scores for the sensory system, 32 scores for the motor system, and 18 scores for the coordination of skeletal muscles.11,16,17
Animal Health Parameters Evaluation To assess the adverse effects produced by hMSCs, the health parameters of each recipient were monitored on a regular basis (see Table 1).
Grouping Following 2 weeks of acclimatization, prestudy examination was done to ensure every monkey was healthy. Then, the monkeys were assigned to 3 groups randomly according to body
Immunology Evaluation At regular intervals, blood was taken from brachial vein of the front limb to examine the immunology parameters. The IgG
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
Feng et al
405
Table 1. Examinations After hMSCs Transplantation. Examination Time
Parameters
1, 2, 3, 4, 5, 8, 11, 15, 19, 23, 27 weeks after the Body weight, body temperature, neurological function evaluation, hematology (red blood first cells transplantation cell, hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular volume, platelet count, white blood cell count and classification, reticulocyte count, and prothrombin time); humoral immunity (IgG and IgM); cellular immunity (CD3, CD4, and CD8). 2, 5, 8, 11, 15, 19, 23, 27 weeks after the first cells Electrocardiogram (heart rate, PR interval, QRS interval, QT interval, QTc); blood transplantation biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, creatine phosphokinase, urea nitrogen, creatinine, total protein, albumin, globulin, glucose, total bilirubin, cholesterol, triglycerides, g-glutamyltransferase, chloride, potassium, sodium); routine urinalysis (appearance, specific gravity, pH, urine glucose, urine protein, urine bilirubin, urobilinogen, ketone body, erythrocyte, and leukocyte); cerebrospinal fluid (appearance, protein, glucose, and chloride) Abbreviations: Ig, immunoglobulin; hMSCs, human mesenchymal stem cells.
and IgM of the serum were determined with fully automatic biochemical analyzer (HITACHI 7020, Japan). The CD3, CD4, and CD8 of the K2EDTA anticoagulated blood were determined with flow cytometry (FACSCalibur, U.S.A BD Co; see Table 1).
Cerebrospinal Fluid Evaluation At regular intervals, the cerebrospinal fluid was extracted to examine the related parameters. The color and transparency of the cerebrospinal fluid were observed with naked eyes. The cells of the cerebrospinal fluid were counted with microscope. The content of protein, glucose, and chloride of the cerebrospinal fluid was determined with fully automatic biochemical analyzer (HITACHI 7020, Japan) and potassium sodium and chloride analyzer (Roche 9180, Switzerland Roche co; see Table 1).
Pathological Evaluation At the fifth week after hMSCs transplantation, 4 monkeys of each group were euthanized and at the 15th and 27th week after hMSCs transplantation, 2 monkeys of each group were euthanized to understand the recovery of possible adverse effect and possible delayed effect. Schematic diagram (Figure 1) of brain dissection illustrated how the brain from individual transplant recipients was segregated into 3- (gray) or 6-mm (white) coronal slices, which are numbered 1 to 13.18 The slices were embedded in paraffin for slicing, and the slice thickness was 5 mm. The slices were stained with hematoxylin and eosin and observed under a light microscope. Necropsy and histological examinations including 33 organs of the monkeys were performed. Major organs and glands were weighed.
Statistical Analysis All computations were carried out using SPSS 13.0 (SPSS Inc., Chicago, Illinois, USA). The data were analyzed by analysis of variance with post hoc analysis. Differences were determined to be significant with P < 0.05.
Results Clinical Observation, Body Temperature, Body Weight, and Food Intake No adverse effects on animal behavior were observed throughout the study. All animals appeared to be healthy and exhibited normal respiration and gross motor coordination; no changes on body secretions (urine and feces) were noted. The body temperature of all animals fluctuated between 37.5 C and 39.5 C over the course of the study which is normal temperature range of M fascicularis. A decrease in food and water intake during the first 3 days after surgery was observed in all of the groups. This change likely attributed to the altered feeding regimens following surgical procedures to ensure adequate nutrition intake. The food and water intake subsequently returned to baseline level. Body weight increased steadily in all monkeys over the study, and no significant differences were found in the 3 groups (P > 0.05). Electrocardiogram functions, including heart rate, PR interval, QRS interval, QT interval, and QTc, were all within the normal range. No significant differences were observed in all groups (P > 0.05). There were no neurological deficits observed in any of the groups, with neurological deficit scores of zero pre- and postoperation (data not shown).
Hematology and Blood Biochemistry No hMSCs related adverse effects were observed in hematology and blood biochemistry parameters at the study. Compared to the control group, the mean corpuscular hemoglobin concentration of the low-dose group and high-dose group increased significantly at the third week after hMSCs transplantation (P < 0.05 and P < .01, respectively); the prothrombin time of the high-dose group increased significantly at the second week after hMSCs transplantation (P < .05); serum chloride concentration of the high-dose group increased significantly at the eighth week after hMSC transplantation
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
406
International Journal of Toxicology 33(5)
Table 2. Neurological Deficit Score for Monkeys After Stroke. Category
Score
Consciousness Normal, consistently alert, strongly aggressive, escape prone Conscious but clouded, strongly aggressive Conscious, poorly aggressive Conscious, light opposition, escape prone Conscious but clouded and accepting Drowsiness, aroused with stimulation Lethargic, eyes open by strong stimulation Stuporous, aroused with persistent stimulation Light coma, reflex movement only Deep coma, no movement Skeletal muscle coordination Normal, walks normally Light, transient abnormality in motor coordination Minimal ataxia, walks with some impairment of gait Ataxia, but able to climb the cage Walks with compelling stimulation, but difficulty in climbing the cage Stands spontaneously, falls within few steps Sits, just able to circle with compelling stimulation Sits or prostrate, can not stand or sit for long duration, with response to compelling stimulation Posed lateral or dorsal recumbency, with response to compelling stimulation No movement, almost with no response to compelling stimulation Sensory system Facial sensation (ipsi-/contralateral, 0-3 2) Concerted reaction to compelling stimulation (aggression, threaten, escape prone, expressing goodwill) Decreased in concerted reaction to compelling stimulation (obvious decreases in aggressive or threatening expressions) Decreased in concerted reaction to compelling stimulation (obvious decreases in expressing goodwill) Absent, does not react to compelling stimulation in any area of face Pinna reflex (ipsi-/contralateral, 0-3 2) Twitches ear normally Slightly reduced in ear twitching, twitches ear by sonic stimulation Obviously reduced in ear twitching, no ear twitching by sonic stimulation Absent, does not move ear by contact stimulation Pain reflex (lower limb, ipsi-/contralateral, 0-5 2) Strong, quick, complete withdrawal by contact stimulation Comparatively quick withdrawal by contact stimulation Comparatively slow withdrawal by contact stimulation Weak, slow, incomplete, or inconsistent withdrawal by contact stimulation Very weak, slow withdrawal by contact stimulation Absent, no withdrawal by contact stimulation Motor system Hand (ipsi-/contralateral, 0-4 2) Normal Light dyskinesia (slow velocity, poor strength, and parasexuality) Reduced strength or skill (comparatively obvious dyskinesia) Obvious dyskinesia (very slow velocity, very poor strength, and parasexuality) Paralysis or useless Leg (ipsi-/contralateral, 0-6 2) Normal Light dyskinesia (slow velocity, poor strength, and parasexuality) Raises with flexion of knee (comparatively obvious dyskinesia) Obvious dyskinesia (very slow velocity, very poor strength, and parasexuality) Can move, but not against gravity Almost can not move Paralysis or useless Upper limb tone (ipsi-/contralateral, 0-3 2) Normal Lightly spastic or flaccid (occasionally raised fingers when grasping) Relatively spastic or flaccid (continue to raised fingers when grasping) Obviously spastic or flaccid Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
0 2 4 6 8 10 16 20 24 28 0 2 4 6 8 10 12 14 16 18
0/0 1/1 2/2 3/3 0/0 1/1 2/2 3/3 0/0 1/1 2/2 3/3 4/4 5/5
0/0 1/1 2/2 3/3 4/4 0/0 1/1 2/2 3/3 4/4 5/5 6/6 0/0 1/1 2/2 3/3 (continued)
Feng et al
407
Table 2. (continued) Category
Score
Lower limb tone (ipsi-/contralateral, 0-3 2) Normal Lightly spastic or flaccid (occasionally raised toes when grasping) Relatively spastic or flaccid (continue to raised toes when grasping) Obviously spastic or flaccid
Figure 1. Schematic illustrating how the brain from individual transplant recipients was segregated into 3- (gray) or 6-mm (white) coronal slices, which are numbered 1to13.
0/0 1/1 2/2 3/3
Figure 2. No significant changes were observed for the cellular immunity parameters (CD3, CD8, CD4, CD4/CD8) at all time point (P > 0.05) except the CD4 content of the high-dose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < .05).
(P < .05). Yet they were all within the normal reference levels and were not considered biologically significant.
Cellular Immunity, Humoral Immunity, and Cerebrospinal Fluid Examination Compared with the control group, no significant differences were observed for the IgG and IgM content in the treated groups after the hMSCs transplantation (P > 0.05). No significant changes were observed for the cellular immunity parameters (CD3þ, CD8þ, CD4þ, and CD4þ/CD8þ) at all time point (P > 0.05) except the CD4 content of the highdose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < 0.05, Figures 2-5). The appearance of the cerebrospinal fluid is transparent and colorless, and no differences were observed with respect to the content of protein, glucose, and chloride of the cerebrospinal fluid in all groups at various time intervals of evaluation.
Organ Weight and Weight Ratio No significant differences for the organ weight and weight ratio were measured in the 3 groups (P > 0.05). The testis
Figure 3. No significant changes were observed for the cellular immunity parameters (CD3, CD8, CD4, CD4/CD8) at all time point (P > 0.05) except the CD4 content of the high-dose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < .05).
weight and weight ratio of 1 animal of the high-dose group decreased at the fifth week after hMSCs transplantation. The testis weight and weight ratio of 1 animal of highdose group increased at the 27th week after hMSCs transplantation.
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
408
International Journal of Toxicology 33(5)
Figure 4. No significant changes were observed for the cellular immunity parameters (CD3, CD8, CD4, CD4/CD8) at all time point (P > 0.05) except the CD4 content of the high-dose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < .05).
Figure 5. No significant changes were observed for the cellular immunity parameters (CD3, CD8, CD4, CD4/CD8) at all time point (P > 0.05) except the CD4 content of the high-dose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < .05).
Necropsy and Histopathology Necropsy observation conducted at 5th, 15th, and 27th week posttransplantation demonstrated a few findings that were not hMSCs related. The following are the detailed individual macroscopic observations. At the fifth week posttransplantation, the color of a small area of the edge of the right liver lobe of animal No. 9 (_, low-dose group) turns yellow. At the 15th week posttransplantation, a few white cyst appeared outside the intestinal wall of animal No. 7 (\, control group) and the biggest of which is 0.8 0.6 0.3 cm 3, and a few red vesicular complexes whose surface are smooth appeared on the ileocecal mucosal surface of animal No. 17 (_, high-dose group). At the 27th week posttransplantation, a notch appeared at the lower pole of the left kidney of animal No. 4 (_, low-dose group), and a few gray white dots whose diameters are 0.1 to 0.3 cm appeared on the liver surface of
animal No.15 (\, low-dose group). No abnormality was discovered for the other animals. The histopathology changes that attributed to the hMSCs were the pathological injury of the injection area of the cerebrum. The cannula injection channel was verified by histological examination for each animal for proper placement within the intended region. At the fifth week posttransplantation, necrosis was observed around the injection site in the brains of the control animals, and a proliferation of hemoglobin-containing foam cells was noted. In the low-dose group, spindle-shaped tissue necrosis and infiltration of inflammatory cells including foam cells and eosinophils of the injection sites were observed, and vessel congestion and vascular cuff around the necrotic site was also observed. In the high-dose group, a larger area of tissue necrosis with granulosis formation was observed around the injection site. Vascular cuff made up of perivascular lymphocytes and eosinophils formed (Figure 6). At the 15th week posttransplantation, in the control group, a needle-like glial scar with hemoglobin-containing foam cell formed in the injection site of the cerebrum. In the low-dose group, local bands of scar tissue was observed with a proliferation of hemoglobin-containing foam cells. In the high-dose group (No. 17), a larger area of tissue necrosis and granulation tissue formed in the injection site. In the necrosis area, inflammatory cells such as foam cells and eosinophils were observed yet the surrounding tissue remained intact and without edema. The cerebrum of the other monkey (No. 24) in the high-dose group revealed bands of scar tissue in the injection site, with a proliferation of hemoglobin-containing foam cells (Figure 7). At the 27th week posttransplantation, the injection sites in all 3 groups exhibited only a needle-like scar formation, with a hemoglobin-containing foam cell proliferation (Figure 8). Histopathological changes not relevant to the hMSCs transplantation were as follows. At the 15th week posttransplantation, multiple cysts were found on jejunum serosal surface of animal No. 7 (\, control group), and chronic inflammation was found on the ileocecal mucosal surface of animal No. 17 (_, high-dose group). At the 27th week posttransplantation, chronic pyelonephritis was found at 2 sides of animal No. 4 (_, low-dose group), local inflammatory cells infiltration were found at renal interstitium of animal No.18 (_, high-dose group), and a few eosinophilic abscess formed on the liver of animal No.15 (\, low-dose group).
Discussion Human mesenchymal stem cells are nonhematopoietic stem cells in bone marrow. It has multidifferentiation potential, which can differentiate crossing blastoderm into parenchymal cells such as osteocytes, chondrocytes, adipocytes, and so on in proper induction condition. At the same time, it has immunomodulatory property and can modulate the bioactivity of immune cells through various ways. According to the unique properties, more attention should be paid to the effect of hMSCs on the immune system and tumorigenesis induction.
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
Feng et al
409
Figure 6. At 5 weeks posttransplant, necrosis was observed around the injection site of the control, and a proliferation of hemoglobin-containing foam cells was noted (A). In the low-dose group, the neural injection sites exhibited tissue necrosis, with infiltration of inflammatory cells (B), including foam cells and eosinophils and vessel congestion around the necrotic site and the blood vessel (C and D). In the high-dose group, a larger area of tissue necrosis with granulosis formation was observed around the injection site (E, F, and H). Perivascular lymphocytes and eosinophils formed around the vascular cuff (G). Control group (A 100); low-dose group (B, C, and D 100); high-dose group (E, F, and G 100; h 400).
Figure 7. At 15 weeks posttransplant, the injection site of the control animal exhibited a needle-like glial scar with hemoglobin-containing foam cell formation (A). In the high-dose group (E and F) and low-dose group (B, C, and D), hemoglobin-containing foam cells and lymphocytes were observed. Control group (A 100); low-dose group (B, C, and D 100); high-dose group (E and F 100).
In our study, detailed histopathological examination including 32 organs of the monkeys was done to explore the tumorigenesis possibility of hMSCs; the count of CD3þ,
CD4þ, and CD8þ lymphocytes in peripheral blood and the content of IgG and IgM in serum of the monkeys were examined to explore the immunomodulatory property; the
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
410
International Journal of Toxicology 33(5)
Figure 8. At 27 weeks posttransplant, the neural injection sites in all 3 treatment groups exhibited only a needle-like scar formation, with a hemoglobin-containing foam cell proliferation. In the low-dose group, the neural injection sites exhibited with inflammatory cells (C), including eosinophils. In the high-dose group, a proliferation of glial cells and pigmentum deposition were observed around the injection site (E and F). Control group (A and B 100); low-dose group (C 100); high-dose group (D 100; E 200; f 200).
neurological function and cerebrospinal fluid of the monkeys were examined considering the intracerebral injection method. The results showed no notable changes in common symptoms, body weight, body temperature, hematology, blood biochemistry, electrocardiogram, routine urinalysis, and cerebrospinal fluid were evident in any monkey after transplantation. The transplantation of hMSCs did not induce neurological function injury or tumorigenesis. Fluorescence-activated cell sorting analysis also did not reveal any significant change in the count of CD3þ, CD4þ, CD8þ, and CD4þ/CD8þ at any time examined except the CD4þ of high-dose group increased significantly compared with the control group at the second week after hMSCs transplantation (P < 0.05), yet it was within normal limits. Liu18 also reports the intracerebral injection of allogeneic MSCs had no significant adverse effect on the immune system of monkeys which coincide with our results. we speculate this may be attributed to the low immunity microenvironment of the cerebrum. The change in the testis weight and weight ratio of particular monkey was discovered, yet the histopathological examination revealed no abnormality. In this study, the monkeys were killed at the age of 3 to 4 years when the testes were in the peak stage of development. Therefore, the change in testis weight and weight ratio was likely due to the development period of the monkey and which have no relationship with hMSCs transplantation.
The histopathologic results showed that local tissue necrosis and inflammation appeared in the injection area of cerebrum. The damage of high-dose and low-dose groups was greater than that of the control group, yet over time, the damage could be repaired gradually. The damage of high-dose group and lowdose group was greater than that of the control group which may be related to these reasons: (1) the rejection reaction of normal brain tissue to hMSCs which induced the local infiltration of inflammatory cells such as foam cells and eosinophils and (2) the death of hMSCs caused by the change in living microenvironment induced greater proliferation of foam cells than that of the control group. At present, the preclinical safety evaluation of hMSCs is still less. Our study systemically evaluated the safety of hMSCs transplantation in the cerebrum. The results are particularly relevant in that the dosage of administered hMSCs was calculated based on the clinical dose planned for use in treating patients. Moreover, each animal was subjected to 2 rounds of cell transplantation, which may be required clinically to achieve a substantial and sustained benefit. The results showed under the dose of 2. 5 106/kg, human BMSC injected in capsula externa region of basal ganglia only induced local pathologic damage of the injection site of cerebrum, and the damage could be repaired gradually which indicates that intracerebral hMSC transplantation in nonhuman primates is safe and produces no observable tumors up to 6 months posttransplantation.
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
Feng et al
411
Conclusion In conclusion, we have demonstrated that the repeated delivery of hMSCs at clinically relevant doses to the basal ganglia region in nonhuman primates is safe. Although some pathological changes were observed in the area of transplantation, these did not result in any neurological deficits or systemic side effects. These data support the use of hMSCs in clinical trials involving treatments for cerebral stroke. Acknowledgments The authors acknowledge Professor Zhaohui Zhu, Professor Wanchen Dou, Dr Xiaohai Liu, and Yu Wang for their advice and technical support.
Author Contribution The first 5 authors contributed equally to this work. Ming Feng contributed to conception and design and gave final approval. Yan Li contributed to conception and gave final approval. Xinjie Bao contributed to design and gave final approval. Qin Han contributed to acquisition, analysis, and interpretation, and gave final approval. Qin Li contributed to analysis and gave final approval. Hua Zhu contributed to analysis and gave final approval. Junji Wei contributed to acquisition and analysis, critically revised manuscript, and gave final approval. Ming Yang contributed to analysis, drafted manuscript, and gave final approval. Wenbin Ma contributed to acquisition and interpretation, critically revised manuscript, and gave final approval. Hong Gao contributed to analysis and gave final approval. Yihua An contributed to acquisition, critically revised manuscript, and gave final approval. Rober Chunhua Zhao contributed to acquisition and interpretation, critically revised manuscript, and gave final approval. Chuan Qin contributed to design, critically revised manuscript, and gave final approval. Renzhi Wang contributed to conception and design, critically revised manuscript, and gave final approval.
Authors’ Note Ming Yang is now in the National University Hospital of Singapore.
Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by grants from the ‘‘863 Project’’ of the Ministry of Science and Technology of the People’s Republic of China (2013AA020106), the National Natural Science Foundation of China (81100869), and the Youth Foundation of Peking Union Medical College Hospital.
References 1. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124-1134. 2. Liu L. Cardiovascular diseases in China. Biochem Cell Biol. 2007; 85(2):157-163.
3. Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the stroke council, American heart association. Stroke. 1999;30(4):905-915. 4. Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344(19):1450-1460. 5. Heiskanen O. Treatment of spontaneous intracerebral and intracerebellar hemorrhages. Stroke. 1993;24(12 suppl): I94-I95; discussion I107-108. 6. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317-1329. 7. Li Y, Chen J, Wang L, Zhang L, Lu M, Chopp M. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neurosci Lett. 2001;316(2):67-70. 8. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009;8(5):491-500. 9. Lee ST, Chu K, Jung KH, et al. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke. Brain. 2008;131(pt 3):616-629. 10. Lee HJ, Kim KS, Kim EJ, et al. Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells. 2007; 25(5):1204-1212. 11. Feng M, Zhu H, Zhu Z, et al. Serial 18F-FDG PET demonstrates benefit of human mesenchymal stem cells in treatment of intracerebral hematoma: a translational study in a primate model. J Nucl Med. 2011;52(1):90-97. 12. Bao X, Feng M, Wei J, et al. Transplantation of Flk-1þ human bone marrow-derived mesenchymal stem cells promotes angiogenesis and neurogenesis after cerebral ischemia in rats. Eur J Neurosci. 2011;34(1):87-98. 13. Bao X, Wei J, Feng M, et al. Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats. Brain Res. 2011;1367:103-113. 14. Trounson A. New perspectives in human stem cell therapeutic research. BMC Med. 2009;7:29. 15. Fang B, Liao L, Shi M, Yang S, Zhao RC. Multipotency of Flk1CD34 progenitors derived from human fetal bone marrow. J Lab Clin Med. 2004;143(4):230-240. 16. Kito G, Nishimura A, Susumu T, et al. Experimental thromboembolic stroke in cynomolgus monkey. J Neurosci Methods. 2001; 105(1):45-53. 17. Edwards DF, Chen YW, Diringer MN. Unified neurological stroke scale is valid in ischemic and hemorrhagic stroke. Stroke. 1995;26(10):1852-1858. 18. Liu L, Sun Z, Chen B, et al. Ex Vivo Expansion and In Vivo Infusion of Bone Marrow-Derived Flk-1+CD31-CD34- Mesenchymal Stem Cells: Feasibility and Safety from Monkey to Human. Stem Cells and development. 2006;(15):349-357.
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
Preclinical Safety Evaluation of Human Mesenchymal Stem Cell Transplantation in Cerebrum of Nonhuman Primates
International Journal of Toxicology 2014, Vol. 33(5) 403-411 ª The Author(s) 2014 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/1091581814545244 ijt.sagepub.com
Ming Feng1, Yan Li2,3, Qin Han4, Xinjie Bao1, Ming Yang1, Hua Zhu2, Qin Li2, Junji Wei1, Wenbin Ma1, Hong Gao2, Yihua An5, Robert Chunhua Zhao4, Chuan Qin2, and Renzhi Wang1
Abstract The efficacy of stem cell transplantation for promoting recovery of patients with neurological diseases, such as stroke, has been reported in several studies. However, the safety of the intracerebral transplantation of human mesenchymal stem cells (hMSCs) remains unclear. The aim of the study was to evaluate the safety of hMSCs transplanted in cerebrum of Macaca fascicularis and to provide evidence for clinical application. A total of 24 M fascicularis were assigned to 3 groups randomly: low dose (3.0 105 cells/kg), high dose (2.5 106 cells/kg), and the control (normal saline [NS]). Human mesenchymal stem cells or NS were injected into each monkey for 2 times, with an interval of 3 weeks. The injection point was located outside of the right putamen, according to a stereotactic map and preoperative magnetic resonance imaging of the monkeys. Animal health, behavior, biophysical and biochemical parameters, and brain neurological function were routinely monitored over a 6-month period posttransplantation, and the histopathologic examinations were also performed. The results showed that local pathologic damage including local tissue necrosis and inflammation was induced after the injection. The damage of low-dose and high-dose groups was greater than that of the control group, yet over time, the damage could be repaired gradually. No major hMSCs-associated changes were induced from other indicators, and the transplantation of hMSCs in monkeys did not affect total immunoglobulin (Ig) M, total IgG, CD3, CD4, or CD8 values. We therefore conclude that transplantation of hMSCs to the cerebrum represents a safe alternative for clinical application of neurological disorders. Keywords mesenchymal stem cell, cell transplantation, safety, cerebrum, Macaca fascicularis
Introduction Cerebrovascular disease (CVD) is a common and lifethreatening disease that poses a significant public health challenge. He et al1 reported in 2005 that CVD ranked the third among 5 leading causes of death in men and ranked the second in women. A multicenter research in China indicated that CVD was the most prevalent cause of deaths, accounting for 40% of total deaths. However, there remain a limited number of effective therapies for CVD, and patients still had continued deterioration of neurological function following treatment.2-6 Consequently, it is important to develop novel therapies that can limit the extent of neurological damage and improve functional recovery. Human mesenchymal stem cells (hMSCs), usually obtained from bone marrow, can differentiate into a variety of cell types and can facilitate damage repair and structural and functional repair of aged organ. Related studies have shown that hMSCsbased therapies promote recovery of motor function in stroke mice model7 and improved neurologic function following
induced stroke.8 These findings have been confirmed and extended by many other animal studies.9-13 Stem cell treatment has also shown benefits in our prior studies using experimental intracerebral hemorrhage models in rodents and primates.11-13 These properties, together with the fact that MSCs can be
1
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China 2 Institute of Laboratory Animal Sciences, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 3 National Institute for Nutrition and Food Safety, Chinese Center for Disease Control and Prevention, Beijing, China 4 Institute of Basic Medical Sciences, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 5 Beijing Institute of Neurological Surgery, Beijing, China Corresponding Author: Renzhi Wang, Department of Neurosurgery of Peking Union Medical College Hospital, 100730, Beijing, People’s Republic of China. Email: [email protected]
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
404
International Journal of Toxicology 33(5)
readily obtained, rapidly expanded in vitro, and has fewer ethical disputes, make them a promising therapeutic candidates to CVD. However, the safety of intracerebral hMSCs transplantation is still unclear; thus, it is urgent to explore this approach in a clinically relevant model.14 The goal of this study was to evaluate the long-term toxicity associated with repeated intracerebral hMSCs transplantation in nonhuman primates (Macaca fascicularis).
Materials and Methods Animals and Housing A total of 24 M fascicularis (12 male and 12 female; aged 3 to 6 years; weight 4.1 + 0.5 kg) were received from the Experimental Animal Center of the Chinese Academy of Military Medical Sciences. All monkeys were kept single in stainless steel cage at 18 C to 28 C and a relative humidity of 40% to 70%. The primate facility is licensed and accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, and all procedures were approved by the Institutional Animal Care and Use Committee of the Chinese Academy of Medical Sciences (MC-07-6004). Animal experiments and housing procedures were carried out in accordance with the laboratory animal administration rules of the Ministry of Science and Technology of the People’s Republic of China.
weight: low dose (3.0 105 cells/kg), high dose (2.5 106 cells/kg), and the control (phosphate-buffered saline), and the dose is 2.1 and 17.5 times to intended clinical dose (1 107 cells/person, the body weight of one person is assumed to be 70 kg), respectively.
Dosing The animals were fasted overnight prior to surgery. Ketamine (15 mg/kg) and sodium pentobarbital (30 mg/kg) were administered intramuscularly (IM) for the duration of the procedure. Then, the monkeys were placed in a stereotactic frame (Stoelting Co, Illinois) and set the origin coordinates according to a stereotactic map and preoperative magnetic resonance imaging (MRI) scans. The coordinates were recorded and the coordinate origin was set. Generally, the coordinates were AP 16 mm, D 16 mm, and L 14 mm, whereby AP represents the anterior and posterior directions, D represents the depth, and L represents the lateral coordinates. The injection point was located outside of the right putamen, according to a stereotactic map and preoperative MRI of the monkeys. The cells were delivered through 2 injection channels located 1.5 mm apart, and each channel contained 3 injection points spaced 1 mm apart. A total volume of 250 mL was administered at a rate of 40 to 50 mL/min. After a 3-week interval, animals were administered a second round of injections using the same procedure. Penicillin (400 000 units per day, IM) was administered for 3 days after surgery.
Preparation of the HMSCs Bone marrow was collected from healthy adult human volunteers. All participants signed a declaration of informed consent before surgery. The hMSCs were isolated and cultured using a technique that has been detailed in a previous report.15 Briefly, mononuclear cells were isolated from marrow aspirates with Ficoll-Paque density gradient centrifugation. Cells were counted and cultured in Dulbecco Modified Eagle Medium: Nutrient Mixture F-12 (Gibco Co, Los Angeles) with 2% fetal bovine serum (Hyclone Co, Utah), 2 mmol/L L-glutamine (Hyclone), 1 insulin transferrin selenium (Gibco), 109 mol/L dexamethasone (Sigma-Aldrich, St. Louis), 104 mol/L ascorbic acid 2-phosphate (Sigma-Aldrich), 10 ng/mL epidermal growth factor, 100 U/mL penicillin, and 1000 U/mL streptomycin (Gibco) at 3 105 cells/cm2 in a humidified incubator at 37 C with an atmosphere of 5% CO2. The hMSCs adhered to the walls and grew, and nonadherent cells were removed after 24 to 48 hours. When reached 80% to 90% confluence, the cells were digested with 0.125% trypsin and replated at a 1:2 dilution under the same culture conditions, then were collected and prepared for transplantation.
General Observations and Examinations Animals were observed daily following surgery. Skin and fur appearance, vital signs, secretions, upper and lower limb movements, consciousness, and injection region reactions were assessed at 1, 2, and 3 days after cell administration.
Neurological Function Evaluation Each monkey was subjected to neurological function tests at regular time intervals (see Table 1). Scores for neurological function were refined and modified from the Kito score scale and also referenced the ‘‘Neurological Scale for Middle Cerebral Artery Infarction’’ (Table 2). The scale includes a total of 100 scores, including 28 scores for awareness, 22 scores for the sensory system, 32 scores for the motor system, and 18 scores for the coordination of skeletal muscles.11,16,17
Animal Health Parameters Evaluation To assess the adverse effects produced by hMSCs, the health parameters of each recipient were monitored on a regular basis (see Table 1).
Grouping Following 2 weeks of acclimatization, prestudy examination was done to ensure every monkey was healthy. Then, the monkeys were assigned to 3 groups randomly according to body
Immunology Evaluation At regular intervals, blood was taken from brachial vein of the front limb to examine the immunology parameters. The IgG
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
Feng et al
405
Table 1. Examinations After hMSCs Transplantation. Examination Time
Parameters
1, 2, 3, 4, 5, 8, 11, 15, 19, 23, 27 weeks after the Body weight, body temperature, neurological function evaluation, hematology (red blood first cells transplantation cell, hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular volume, platelet count, white blood cell count and classification, reticulocyte count, and prothrombin time); humoral immunity (IgG and IgM); cellular immunity (CD3, CD4, and CD8). 2, 5, 8, 11, 15, 19, 23, 27 weeks after the first cells Electrocardiogram (heart rate, PR interval, QRS interval, QT interval, QTc); blood transplantation biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, creatine phosphokinase, urea nitrogen, creatinine, total protein, albumin, globulin, glucose, total bilirubin, cholesterol, triglycerides, g-glutamyltransferase, chloride, potassium, sodium); routine urinalysis (appearance, specific gravity, pH, urine glucose, urine protein, urine bilirubin, urobilinogen, ketone body, erythrocyte, and leukocyte); cerebrospinal fluid (appearance, protein, glucose, and chloride) Abbreviations: Ig, immunoglobulin; hMSCs, human mesenchymal stem cells.
and IgM of the serum were determined with fully automatic biochemical analyzer (HITACHI 7020, Japan). The CD3, CD4, and CD8 of the K2EDTA anticoagulated blood were determined with flow cytometry (FACSCalibur, U.S.A BD Co; see Table 1).
Cerebrospinal Fluid Evaluation At regular intervals, the cerebrospinal fluid was extracted to examine the related parameters. The color and transparency of the cerebrospinal fluid were observed with naked eyes. The cells of the cerebrospinal fluid were counted with microscope. The content of protein, glucose, and chloride of the cerebrospinal fluid was determined with fully automatic biochemical analyzer (HITACHI 7020, Japan) and potassium sodium and chloride analyzer (Roche 9180, Switzerland Roche co; see Table 1).
Pathological Evaluation At the fifth week after hMSCs transplantation, 4 monkeys of each group were euthanized and at the 15th and 27th week after hMSCs transplantation, 2 monkeys of each group were euthanized to understand the recovery of possible adverse effect and possible delayed effect. Schematic diagram (Figure 1) of brain dissection illustrated how the brain from individual transplant recipients was segregated into 3- (gray) or 6-mm (white) coronal slices, which are numbered 1 to 13.18 The slices were embedded in paraffin for slicing, and the slice thickness was 5 mm. The slices were stained with hematoxylin and eosin and observed under a light microscope. Necropsy and histological examinations including 33 organs of the monkeys were performed. Major organs and glands were weighed.
Statistical Analysis All computations were carried out using SPSS 13.0 (SPSS Inc., Chicago, Illinois, USA). The data were analyzed by analysis of variance with post hoc analysis. Differences were determined to be significant with P < 0.05.
Results Clinical Observation, Body Temperature, Body Weight, and Food Intake No adverse effects on animal behavior were observed throughout the study. All animals appeared to be healthy and exhibited normal respiration and gross motor coordination; no changes on body secretions (urine and feces) were noted. The body temperature of all animals fluctuated between 37.5 C and 39.5 C over the course of the study which is normal temperature range of M fascicularis. A decrease in food and water intake during the first 3 days after surgery was observed in all of the groups. This change likely attributed to the altered feeding regimens following surgical procedures to ensure adequate nutrition intake. The food and water intake subsequently returned to baseline level. Body weight increased steadily in all monkeys over the study, and no significant differences were found in the 3 groups (P > 0.05). Electrocardiogram functions, including heart rate, PR interval, QRS interval, QT interval, and QTc, were all within the normal range. No significant differences were observed in all groups (P > 0.05). There were no neurological deficits observed in any of the groups, with neurological deficit scores of zero pre- and postoperation (data not shown).
Hematology and Blood Biochemistry No hMSCs related adverse effects were observed in hematology and blood biochemistry parameters at the study. Compared to the control group, the mean corpuscular hemoglobin concentration of the low-dose group and high-dose group increased significantly at the third week after hMSCs transplantation (P < 0.05 and P < .01, respectively); the prothrombin time of the high-dose group increased significantly at the second week after hMSCs transplantation (P < .05); serum chloride concentration of the high-dose group increased significantly at the eighth week after hMSC transplantation
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
406
International Journal of Toxicology 33(5)
Table 2. Neurological Deficit Score for Monkeys After Stroke. Category
Score
Consciousness Normal, consistently alert, strongly aggressive, escape prone Conscious but clouded, strongly aggressive Conscious, poorly aggressive Conscious, light opposition, escape prone Conscious but clouded and accepting Drowsiness, aroused with stimulation Lethargic, eyes open by strong stimulation Stuporous, aroused with persistent stimulation Light coma, reflex movement only Deep coma, no movement Skeletal muscle coordination Normal, walks normally Light, transient abnormality in motor coordination Minimal ataxia, walks with some impairment of gait Ataxia, but able to climb the cage Walks with compelling stimulation, but difficulty in climbing the cage Stands spontaneously, falls within few steps Sits, just able to circle with compelling stimulation Sits or prostrate, can not stand or sit for long duration, with response to compelling stimulation Posed lateral or dorsal recumbency, with response to compelling stimulation No movement, almost with no response to compelling stimulation Sensory system Facial sensation (ipsi-/contralateral, 0-3 2) Concerted reaction to compelling stimulation (aggression, threaten, escape prone, expressing goodwill) Decreased in concerted reaction to compelling stimulation (obvious decreases in aggressive or threatening expressions) Decreased in concerted reaction to compelling stimulation (obvious decreases in expressing goodwill) Absent, does not react to compelling stimulation in any area of face Pinna reflex (ipsi-/contralateral, 0-3 2) Twitches ear normally Slightly reduced in ear twitching, twitches ear by sonic stimulation Obviously reduced in ear twitching, no ear twitching by sonic stimulation Absent, does not move ear by contact stimulation Pain reflex (lower limb, ipsi-/contralateral, 0-5 2) Strong, quick, complete withdrawal by contact stimulation Comparatively quick withdrawal by contact stimulation Comparatively slow withdrawal by contact stimulation Weak, slow, incomplete, or inconsistent withdrawal by contact stimulation Very weak, slow withdrawal by contact stimulation Absent, no withdrawal by contact stimulation Motor system Hand (ipsi-/contralateral, 0-4 2) Normal Light dyskinesia (slow velocity, poor strength, and parasexuality) Reduced strength or skill (comparatively obvious dyskinesia) Obvious dyskinesia (very slow velocity, very poor strength, and parasexuality) Paralysis or useless Leg (ipsi-/contralateral, 0-6 2) Normal Light dyskinesia (slow velocity, poor strength, and parasexuality) Raises with flexion of knee (comparatively obvious dyskinesia) Obvious dyskinesia (very slow velocity, very poor strength, and parasexuality) Can move, but not against gravity Almost can not move Paralysis or useless Upper limb tone (ipsi-/contralateral, 0-3 2) Normal Lightly spastic or flaccid (occasionally raised fingers when grasping) Relatively spastic or flaccid (continue to raised fingers when grasping) Obviously spastic or flaccid Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
0 2 4 6 8 10 16 20 24 28 0 2 4 6 8 10 12 14 16 18
0/0 1/1 2/2 3/3 0/0 1/1 2/2 3/3 0/0 1/1 2/2 3/3 4/4 5/5
0/0 1/1 2/2 3/3 4/4 0/0 1/1 2/2 3/3 4/4 5/5 6/6 0/0 1/1 2/2 3/3 (continued)
Feng et al
407
Table 2. (continued) Category
Score
Lower limb tone (ipsi-/contralateral, 0-3 2) Normal Lightly spastic or flaccid (occasionally raised toes when grasping) Relatively spastic or flaccid (continue to raised toes when grasping) Obviously spastic or flaccid
Figure 1. Schematic illustrating how the brain from individual transplant recipients was segregated into 3- (gray) or 6-mm (white) coronal slices, which are numbered 1to13.
0/0 1/1 2/2 3/3
Figure 2. No significant changes were observed for the cellular immunity parameters (CD3, CD8, CD4, CD4/CD8) at all time point (P > 0.05) except the CD4 content of the high-dose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < .05).
(P < .05). Yet they were all within the normal reference levels and were not considered biologically significant.
Cellular Immunity, Humoral Immunity, and Cerebrospinal Fluid Examination Compared with the control group, no significant differences were observed for the IgG and IgM content in the treated groups after the hMSCs transplantation (P > 0.05). No significant changes were observed for the cellular immunity parameters (CD3þ, CD8þ, CD4þ, and CD4þ/CD8þ) at all time point (P > 0.05) except the CD4 content of the highdose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < 0.05, Figures 2-5). The appearance of the cerebrospinal fluid is transparent and colorless, and no differences were observed with respect to the content of protein, glucose, and chloride of the cerebrospinal fluid in all groups at various time intervals of evaluation.
Organ Weight and Weight Ratio No significant differences for the organ weight and weight ratio were measured in the 3 groups (P > 0.05). The testis
Figure 3. No significant changes were observed for the cellular immunity parameters (CD3, CD8, CD4, CD4/CD8) at all time point (P > 0.05) except the CD4 content of the high-dose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < .05).
weight and weight ratio of 1 animal of the high-dose group decreased at the fifth week after hMSCs transplantation. The testis weight and weight ratio of 1 animal of highdose group increased at the 27th week after hMSCs transplantation.
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
408
International Journal of Toxicology 33(5)
Figure 4. No significant changes were observed for the cellular immunity parameters (CD3, CD8, CD4, CD4/CD8) at all time point (P > 0.05) except the CD4 content of the high-dose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < .05).
Figure 5. No significant changes were observed for the cellular immunity parameters (CD3, CD8, CD4, CD4/CD8) at all time point (P > 0.05) except the CD4 content of the high-dose group increased significantly compared to the control group at the second week after the hMSCs transplantation (P < .05).
Necropsy and Histopathology Necropsy observation conducted at 5th, 15th, and 27th week posttransplantation demonstrated a few findings that were not hMSCs related. The following are the detailed individual macroscopic observations. At the fifth week posttransplantation, the color of a small area of the edge of the right liver lobe of animal No. 9 (_, low-dose group) turns yellow. At the 15th week posttransplantation, a few white cyst appeared outside the intestinal wall of animal No. 7 (\, control group) and the biggest of which is 0.8 0.6 0.3 cm 3, and a few red vesicular complexes whose surface are smooth appeared on the ileocecal mucosal surface of animal No. 17 (_, high-dose group). At the 27th week posttransplantation, a notch appeared at the lower pole of the left kidney of animal No. 4 (_, low-dose group), and a few gray white dots whose diameters are 0.1 to 0.3 cm appeared on the liver surface of
animal No.15 (\, low-dose group). No abnormality was discovered for the other animals. The histopathology changes that attributed to the hMSCs were the pathological injury of the injection area of the cerebrum. The cannula injection channel was verified by histological examination for each animal for proper placement within the intended region. At the fifth week posttransplantation, necrosis was observed around the injection site in the brains of the control animals, and a proliferation of hemoglobin-containing foam cells was noted. In the low-dose group, spindle-shaped tissue necrosis and infiltration of inflammatory cells including foam cells and eosinophils of the injection sites were observed, and vessel congestion and vascular cuff around the necrotic site was also observed. In the high-dose group, a larger area of tissue necrosis with granulosis formation was observed around the injection site. Vascular cuff made up of perivascular lymphocytes and eosinophils formed (Figure 6). At the 15th week posttransplantation, in the control group, a needle-like glial scar with hemoglobin-containing foam cell formed in the injection site of the cerebrum. In the low-dose group, local bands of scar tissue was observed with a proliferation of hemoglobin-containing foam cells. In the high-dose group (No. 17), a larger area of tissue necrosis and granulation tissue formed in the injection site. In the necrosis area, inflammatory cells such as foam cells and eosinophils were observed yet the surrounding tissue remained intact and without edema. The cerebrum of the other monkey (No. 24) in the high-dose group revealed bands of scar tissue in the injection site, with a proliferation of hemoglobin-containing foam cells (Figure 7). At the 27th week posttransplantation, the injection sites in all 3 groups exhibited only a needle-like scar formation, with a hemoglobin-containing foam cell proliferation (Figure 8). Histopathological changes not relevant to the hMSCs transplantation were as follows. At the 15th week posttransplantation, multiple cysts were found on jejunum serosal surface of animal No. 7 (\, control group), and chronic inflammation was found on the ileocecal mucosal surface of animal No. 17 (_, high-dose group). At the 27th week posttransplantation, chronic pyelonephritis was found at 2 sides of animal No. 4 (_, low-dose group), local inflammatory cells infiltration were found at renal interstitium of animal No.18 (_, high-dose group), and a few eosinophilic abscess formed on the liver of animal No.15 (\, low-dose group).
Discussion Human mesenchymal stem cells are nonhematopoietic stem cells in bone marrow. It has multidifferentiation potential, which can differentiate crossing blastoderm into parenchymal cells such as osteocytes, chondrocytes, adipocytes, and so on in proper induction condition. At the same time, it has immunomodulatory property and can modulate the bioactivity of immune cells through various ways. According to the unique properties, more attention should be paid to the effect of hMSCs on the immune system and tumorigenesis induction.
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
Feng et al
409
Figure 6. At 5 weeks posttransplant, necrosis was observed around the injection site of the control, and a proliferation of hemoglobin-containing foam cells was noted (A). In the low-dose group, the neural injection sites exhibited tissue necrosis, with infiltration of inflammatory cells (B), including foam cells and eosinophils and vessel congestion around the necrotic site and the blood vessel (C and D). In the high-dose group, a larger area of tissue necrosis with granulosis formation was observed around the injection site (E, F, and H). Perivascular lymphocytes and eosinophils formed around the vascular cuff (G). Control group (A 100); low-dose group (B, C, and D 100); high-dose group (E, F, and G 100; h 400).
Figure 7. At 15 weeks posttransplant, the injection site of the control animal exhibited a needle-like glial scar with hemoglobin-containing foam cell formation (A). In the high-dose group (E and F) and low-dose group (B, C, and D), hemoglobin-containing foam cells and lymphocytes were observed. Control group (A 100); low-dose group (B, C, and D 100); high-dose group (E and F 100).
In our study, detailed histopathological examination including 32 organs of the monkeys was done to explore the tumorigenesis possibility of hMSCs; the count of CD3þ,
CD4þ, and CD8þ lymphocytes in peripheral blood and the content of IgG and IgM in serum of the monkeys were examined to explore the immunomodulatory property; the
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
410
International Journal of Toxicology 33(5)
Figure 8. At 27 weeks posttransplant, the neural injection sites in all 3 treatment groups exhibited only a needle-like scar formation, with a hemoglobin-containing foam cell proliferation. In the low-dose group, the neural injection sites exhibited with inflammatory cells (C), including eosinophils. In the high-dose group, a proliferation of glial cells and pigmentum deposition were observed around the injection site (E and F). Control group (A and B 100); low-dose group (C 100); high-dose group (D 100; E 200; f 200).
neurological function and cerebrospinal fluid of the monkeys were examined considering the intracerebral injection method. The results showed no notable changes in common symptoms, body weight, body temperature, hematology, blood biochemistry, electrocardiogram, routine urinalysis, and cerebrospinal fluid were evident in any monkey after transplantation. The transplantation of hMSCs did not induce neurological function injury or tumorigenesis. Fluorescence-activated cell sorting analysis also did not reveal any significant change in the count of CD3þ, CD4þ, CD8þ, and CD4þ/CD8þ at any time examined except the CD4þ of high-dose group increased significantly compared with the control group at the second week after hMSCs transplantation (P < 0.05), yet it was within normal limits. Liu18 also reports the intracerebral injection of allogeneic MSCs had no significant adverse effect on the immune system of monkeys which coincide with our results. we speculate this may be attributed to the low immunity microenvironment of the cerebrum. The change in the testis weight and weight ratio of particular monkey was discovered, yet the histopathological examination revealed no abnormality. In this study, the monkeys were killed at the age of 3 to 4 years when the testes were in the peak stage of development. Therefore, the change in testis weight and weight ratio was likely due to the development period of the monkey and which have no relationship with hMSCs transplantation.
The histopathologic results showed that local tissue necrosis and inflammation appeared in the injection area of cerebrum. The damage of high-dose and low-dose groups was greater than that of the control group, yet over time, the damage could be repaired gradually. The damage of high-dose group and lowdose group was greater than that of the control group which may be related to these reasons: (1) the rejection reaction of normal brain tissue to hMSCs which induced the local infiltration of inflammatory cells such as foam cells and eosinophils and (2) the death of hMSCs caused by the change in living microenvironment induced greater proliferation of foam cells than that of the control group. At present, the preclinical safety evaluation of hMSCs is still less. Our study systemically evaluated the safety of hMSCs transplantation in the cerebrum. The results are particularly relevant in that the dosage of administered hMSCs was calculated based on the clinical dose planned for use in treating patients. Moreover, each animal was subjected to 2 rounds of cell transplantation, which may be required clinically to achieve a substantial and sustained benefit. The results showed under the dose of 2. 5 106/kg, human BMSC injected in capsula externa region of basal ganglia only induced local pathologic damage of the injection site of cerebrum, and the damage could be repaired gradually which indicates that intracerebral hMSC transplantation in nonhuman primates is safe and produces no observable tumors up to 6 months posttransplantation.
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
Feng et al
411
Conclusion In conclusion, we have demonstrated that the repeated delivery of hMSCs at clinically relevant doses to the basal ganglia region in nonhuman primates is safe. Although some pathological changes were observed in the area of transplantation, these did not result in any neurological deficits or systemic side effects. These data support the use of hMSCs in clinical trials involving treatments for cerebral stroke. Acknowledgments The authors acknowledge Professor Zhaohui Zhu, Professor Wanchen Dou, Dr Xiaohai Liu, and Yu Wang for their advice and technical support.
Author Contribution The first 5 authors contributed equally to this work. Ming Feng contributed to conception and design and gave final approval. Yan Li contributed to conception and gave final approval. Xinjie Bao contributed to design and gave final approval. Qin Han contributed to acquisition, analysis, and interpretation, and gave final approval. Qin Li contributed to analysis and gave final approval. Hua Zhu contributed to analysis and gave final approval. Junji Wei contributed to acquisition and analysis, critically revised manuscript, and gave final approval. Ming Yang contributed to analysis, drafted manuscript, and gave final approval. Wenbin Ma contributed to acquisition and interpretation, critically revised manuscript, and gave final approval. Hong Gao contributed to analysis and gave final approval. Yihua An contributed to acquisition, critically revised manuscript, and gave final approval. Rober Chunhua Zhao contributed to acquisition and interpretation, critically revised manuscript, and gave final approval. Chuan Qin contributed to design, critically revised manuscript, and gave final approval. Renzhi Wang contributed to conception and design, critically revised manuscript, and gave final approval.
Authors’ Note Ming Yang is now in the National University Hospital of Singapore.
Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by grants from the ‘‘863 Project’’ of the Ministry of Science and Technology of the People’s Republic of China (2013AA020106), the National Natural Science Foundation of China (81100869), and the Youth Foundation of Peking Union Medical College Hospital.
References 1. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124-1134. 2. Liu L. Cardiovascular diseases in China. Biochem Cell Biol. 2007; 85(2):157-163.
3. Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the stroke council, American heart association. Stroke. 1999;30(4):905-915. 4. Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344(19):1450-1460. 5. Heiskanen O. Treatment of spontaneous intracerebral and intracerebellar hemorrhages. Stroke. 1993;24(12 suppl): I94-I95; discussion I107-108. 6. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317-1329. 7. Li Y, Chen J, Wang L, Zhang L, Lu M, Chopp M. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neurosci Lett. 2001;316(2):67-70. 8. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009;8(5):491-500. 9. Lee ST, Chu K, Jung KH, et al. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke. Brain. 2008;131(pt 3):616-629. 10. Lee HJ, Kim KS, Kim EJ, et al. Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells. 2007; 25(5):1204-1212. 11. Feng M, Zhu H, Zhu Z, et al. Serial 18F-FDG PET demonstrates benefit of human mesenchymal stem cells in treatment of intracerebral hematoma: a translational study in a primate model. J Nucl Med. 2011;52(1):90-97. 12. Bao X, Feng M, Wei J, et al. Transplantation of Flk-1þ human bone marrow-derived mesenchymal stem cells promotes angiogenesis and neurogenesis after cerebral ischemia in rats. Eur J Neurosci. 2011;34(1):87-98. 13. Bao X, Wei J, Feng M, et al. Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats. Brain Res. 2011;1367:103-113. 14. Trounson A. New perspectives in human stem cell therapeutic research. BMC Med. 2009;7:29. 15. Fang B, Liao L, Shi M, Yang S, Zhao RC. Multipotency of Flk1CD34 progenitors derived from human fetal bone marrow. J Lab Clin Med. 2004;143(4):230-240. 16. Kito G, Nishimura A, Susumu T, et al. Experimental thromboembolic stroke in cynomolgus monkey. J Neurosci Methods. 2001; 105(1):45-53. 17. Edwards DF, Chen YW, Diringer MN. Unified neurological stroke scale is valid in ischemic and hemorrhagic stroke. Stroke. 1995;26(10):1852-1858. 18. Liu L, Sun Z, Chen B, et al. Ex Vivo Expansion and In Vivo Infusion of Bone Marrow-Derived Flk-1+CD31-CD34- Mesenchymal Stem Cells: Feasibility and Safety from Monkey to Human. Stem Cells and development. 2006;(15):349-357.
Downloaded from ijt.sagepub.com at Bobst Library, New York University on May 21, 2015
